NEWS

We are excited to share the news that NovoPedics' total meniscus replacement device currently in development recently received  Breakthrough Device Designation from the U.S. Food and Drug Administration.

​

Click to view:

Novopedics press release

Novopedics website 

​

FVCG invested in NovoPedics in 2013.

​We are excited to share the news that Visikol has been acquired by CELLINK. Visikol was founded in 2016 by entrepreneurs at Rutgers University. Visikol is a contract research services company focusing on accelerating the discovery and development of therapeutics by providing pharmaceutical and biotech companies with best-in-class cell culture, 3D tissue imaging, multiplex imaging and digital pathology services. 

​

​

​

​